[ET Net News Agency, 13 September 2021] Shanghai Junshi Biosciences Co., Ltd. (01877)
said it has received the Acceptance Notice issued by the National Medical Products
Administration. The investigational new drug application for the JS012 injection (project
code: JS012) has been accepted.
The active ingredient of JS012 injection is recombinant humanised anti-Claudin18.2
monoclonal antibody, which can target Claudin18.2, inhibit related signal pathway, kill
tumour cells by initiating antibody-dependent cell-mediated cytotoxicity (ADCC) and
complement-dependent cytotoxicity (CDC), and is intended to be used for the treatment of
advanced malignant tumours, such as gastric cancer and pancreatic cancer. (RC)